»ý¸®Åë Ä¡·á ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2031³â)
Dysmenorrhea Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024 - 2031
»óǰÄÚµå
:
1525982
¸®¼Ä¡»ç
:
Persistence Market Research
¹ßÇàÀÏ
:
2024³â 07¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 246 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Persistence Market Research´Â ÃÖ±Ù ¼¼°è »ý¸®Åë Ä¡·áÁ¦ ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ º¸°í¼¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ º¸°í¼´Â ½ÃÀå ÃËÁø¿äÀÎ, µ¿Çâ, ±âȸ ¹× °úÁ¦¸¦ Æ÷ÇÔÇÑ ÁÖ¿ä ½ÃÀå ¿ªÇÐÀ» öÀúÈ÷ Æò°¡ÇÏ°í ½ÃÀå ±¸Á¶¿¡ ´ëÇÑ ½ÉÃþÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.
ÁÖ¿ä ÀλçÀÌÆ®
»ý¸®Åë Ä¡·á ½ÃÀå ±Ô¸ð(2024³â) : 61¾ï ´Þ·¯
¿¹»ó ½ÃÀå ±Ô¸ð(2031³â) : 109¾ï ´Þ·¯
¼¼°è ½ÃÀå ¼ºÀå·ü(2024-2031³â CAGR) : 8.6%
»ý¸®Åë Ä¡·á ½ÃÀå - º¸°í¼ ¹üÀ§:
ÅëÁõÀ» µ¿¹ÝÇÑ »ý¸®ÅëÀÌ Æ¯Â¡ÀÎ »ý¸®ÅëÀº Àü ¼¼°è ¿©¼º Àα¸ÀÇ »ó´ç¼ö°¡ °Þ°í ÀÖ´Â ÁúȯÀÔ´Ï´Ù. »ý¸®Åë Ä¡·á ½ÃÀåÀº ÀǾàǰ, ½ÃÆÇµÇ´Â ÁøÅëÁ¦, È£¸£¸ó Ä¡·á, ´ëüÀÇÇÐ µî ´Ù¾çÇÑ Ä¡·á ¿É¼ÇÀ¸·Î ±¸¼ºµÅ ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº »ý¸®Åë À¯º´·ü Áõ°¡, Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Áõ»ó °ü¸® ¹× ȯÀÚ »îÀÇ Áú Çâ»óÀ» À§ÇÑ ÀÇÇÐ ¿¬±¸ÀÇ ¹ßÀüÀÔ´Ï´Ù.
½ÃÀå ÃËÁø¿äÀÎ:
¼¼°è »ý¸®Åë Ä¡·á ½ÃÀåÀº È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀÇ °¡¿ë¼º¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡¿Í °¡Àӱ⠿©¼ºÀÇ »ý¸®Åë À¯º´·ü Áõ°¡ µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¾à¹° Á¦Á¦ÀÇ ¹ßÀü°ú ºñÈ£¸£¸óÁ¦ ¹× Ç¥Àû Ä¡·á¿Í °°Àº »õ·Î¿î Ä¡·á¹ýÀÇ °³¹ßÀÌ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼±Áø±¹°ú ½ÅÈï ½ÃÀå ¸ðµÎ¿¡¼ ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í ´Ù¾çÇÑ Ä¡·á ¿É¼ÇÀÇ °¡¿ë¼ºÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¾ïÁ¦¿äÀÎ:
À¯¸ÁÇÑ ¼ºÀå Àü¸Á¿¡µµ ºÒ±¸Çϰí, »ý¸®Åë Ä¡·á ½ÃÀåÀº °í±Þ Ä¡·á ¿É¼ÇÀÇ ³ôÀº ºñ¿ë°ú ƯÁ¤ Áö¿ªÀÇ Á¦ÇÑµÈ ÀÇ·á ¼ºñ½º Á¢±Ù¼º°ú °ü·ÃµÈ µµÀü¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ä¡·á È¿°úÀÇ ÆíÂ÷¿Í ȯÀÚµéÀÇ Ä¡·á ¼øÀÀµµ ¹®Á¦µµ ÇØ°áÇØ¾ß ÇÒ °úÁ¦ÀÔ´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ À庮°ú »õ·Î¿î Ä¡·á¹ýÀ» °ËÁõÇϱâ À§ÇÑ Áö¼ÓÀûÀÎ ÀÓ»ó½ÃÇèÀÇ Çʿ伺Àº ½ÃÀå ¿ªÇп¡ ¿µÇâÀ» ¹ÌÄ¡°í Çõ½ÅÀûÀÎ Ä¡·á ¼Ö·ç¼ÇÀÇ µµÀÔÀ» Áö¿¬½Ãų ¼ö ÀÖ½À´Ï´Ù.
½ÃÀå ±âȸ:
»ý¸®Åë Ä¡·á ½ÃÀåÀº ±â¼ú Çõ½Å, R&D ÅõÀÚ Áõ°¡, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡·Î ÀÎÇØ Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. Áõ»ó ÃßÀûÀ» À§ÇÑ ¸ð¹ÙÀÏ °Ç° ¾Û ¹× ¿ø°ÝÀÇ·á Ç÷§Æû°ú °°Àº µðÁöÅÐ °Ç° ±â¼úÀÇ ÅëÇÕÀº ȯÀÚÀÇ Ä¡·á Á¢±Ù¼ºÀ» °ÈÇϰí Ä¡·á ¼øÀÀµµ¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ý¸®Åë°ú ±× Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀÎ½Ä Á¦°í Ä·ÆäÀΰú ±³À° ÇÁ·Î±×·¥ÀÇ È®´ë´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí Á¶±â Áø´Ü°ú È¿°úÀûÀÎ °ü¸®¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.
º» º¸°í¼¿¡¼ ´Ù·ç´Â ÁÖ¿ä Áú¹®µé
¼¼°è »ý¸®Åë Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
»ý¸®Åë Ä¡·á¿¡ °¡Àå È¿°úÀûÀÎ Ä¡·á ¿É¼Ç°ú Á¢±Ù¹ýÀº ¹«¾ùÀΰ¡?
±â¼ú ¹ßÀü°ú ¿¬±¸ Çõ½ÅÀº »ý¸®Åë Ä¡·á ½ÃÀåÀÇ °æÀï ±¸µµ¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?
»ý¸®Åë Ä¡·á ½ÃÀå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ±â¾÷Àº ¾îµðÀ̸ç, ½ÃÀå °ü·Ã¼ºÀ» À¯ÁöÇϱâ À§ÇØ ¾î¶² Àü·«À» äÅÃÇϰí Àִ°¡?
¼¼°è »ý¸®Åë Ä¡·á ½ÃÀåÀÇ »õ·Î¿î Æ®·»µå¿Í ÇâÈÄ Àü¸ÁÀº?
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå °³¿ä
½ÃÀå ¹üÀ§¿Í Á¤ÀÇ
½ÃÀå ¿ªÇÐ
¼ºÀå ÃËÁø¿äÀÎ
¼ºÀå ¾ïÁ¦¿äÀÎ
±âȸ
°úÁ¦
ÁÖ¿ä µ¿Çâ
Áúȯ ¼ö¸íÁֱ⠺м®
»ý¸®Åë Ä¡·á ½ÃÀå : ¹ë·ùüÀÎ
¿øÀç·á °ø±Þ¾÷ü ¸®½ºÆ®
Á¦Á¶¾÷ü ¸®½ºÆ®
ÆÇ¸Å´ë¸®Á¡ ¸®½ºÆ®
¾ÖÇø®ÄÉÀÌ¼Ç ¸®½ºÆ®
¼öÀͼº ºÐ¼®
Porter¡¯s Five Forces ºÐ¼®
ÁöÁ¤ÇÐÀû ±äÀå : ½ÃÀå¿¡ ´ëÇÑ ¿µÇâ
°Å½Ã°æÁ¦ ¿äÀÎ
¼¼°èÀÇ ºÎ¹®º° Àü¸Á
¼¼°èÀÇ GDP ¼ºÀå Àü¸Á
¼¼°èÀÇ »óºÎ ½ÃÀå °³¿ä
¿¹Ãø¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
±ÔÁ¦¿Í Å×Å©³î·¯Áö »óȲ
Á¦3Àå ¼¼°èÀÇ »ý¸®Åë Ä¡·á ½ÃÀå Àü¸Á : °ú°Å ¹× ¿¹Ãø
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
½ÃÀå ±Ô¸ð ¿¹Ãø
½ÃÀå ±Ô¸ð¿Í Àü³âºñ ¼ºÀå·ü
Àý´ëÀûÀÎ $ ±âȸ
½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, 2019-2023
ÇöÀç ½ÃÀå ±Ô¸ð ¿¹Ãø, 2024-2031
¼¼°èÀÇ »ý¸®Åë Ä¡·á ½ÃÀå Àü¸Á : Áúȯº°
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¼ö·® ºÐ¼® : Áúȯº°, 2019-2023³â
ÇöÀç ¹× ÇâÈÄ ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¼ö·® ¿¹Ãø, Áúȯº°, 2024-2031³â
¿ø¹ß¼º »ý¸®Åë
ÀÌÂ÷¼º »ý¸®Åë
Àڱ󻸷Áõ
Àڱü±±ÙÁõ
ÀڱñÙÁ¾
Àڱ󻸷 Æú¸³
°æ°ü ÇùÂøÁõ
»ý½Ä°ü Æó¼â¼º ±âÇü
½ÃÀå ¸Å·Â ºÐ¼® : Áúȯº°
¼¼°èÀÇ »ý¸®Åë Ä¡·á ½ÃÀå Àü¸Á : Ä¡·á Ŭ·¡½ºº°
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¼ö·® ºÐ¼® : Ä¡·á Ŭ·¡½ºº°, 2019-2023³â
ÇöÀç ¹× ÇâÈÄ ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¼ö·® ¿¹Ãø, Ä¡·á Ŭ·¡½ºº°, 2024-2031³â
ºñÈ£¸£¸ó Ä¡·á
ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦(NSAID)
ºñ¼±ÅÃÀû NSAID
COX-2 ¾ïÁ¦Á¦
°æÇÇ Èí¼öÇü ±Û¸®¼¼¸± Æ®¸®´ÏÆ®·¹ÀÌÆ®
½ÃÆÇ¾à(OTC)
È£¸£¸óÁ¦¿¡ ÀÇÇÑ Ä¡·á
º¹ÇÕ °æ±¸ ÇÇÀÓ¾à
ÇÁ·Î°Ô½ºÆ¾ ¿ä¹ý
·¹º¸³ë¸£°Ô½ºÆ®·¼ Àڱó» ½Ã½ºÅÛ(LN-IUS)
¿Ü°úÀû Ä¡·á ¼±ÅûçÇ×
º¹°°æ °Ë»ç
Àڱà ÀûÃâ
¼±°ñÀü½Å°æ ÀýÁ¦¼ú
º¹°°æÇÏ ÀÚ±Ãõ°ñ ½Å°æ ÀýÁ¦¼ú(LUNA)
Àڱó» ÇÇÀӱⱸ(IUD)
½ÃÀå ¸Å·Â ºÐ¼® : Ä¡·á Ŭ·¡½ºº°
Á¦4Àå ¼¼°èÀÇ »ý¸®Åë Ä¡·á ½ÃÀå Àü¸Á : Áö¿ªº°
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°ú°Å ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¼ö·® ºÐ¼® : Áö¿ªº°, 2019-2023³â
ÇöÀç ¹× ÇâÈÄ ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¼ö·® ¿¹Ãø, Áö¿ªº°, 2024-2031³â
ºÏ¹Ì
À¯·´
µ¿¾Æ½Ã¾Æ
³²¾Æ½Ã¾Æ¿Í ¿À¼¼¾Æ´Ï¾Æ
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
½ÃÀå ¸Å·Â ºÐ¼® : Áö¿ªº°
Á¦5Àå ºÏ¹ÌÀÇ »ý¸®Åë Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â) ¹× ¿¹Ãø(2024-2031³â)
Á¦6Àå À¯·´ÀÇ »ý¸®Åë Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â) ¹× ¿¹Ãø(2024-2031³â)
Á¦7Àå µ¿¾Æ½Ã¾ÆÀÇ »ý¸®Åë Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â) ¹× ¿¹Ãø(2024-2031³â)
Á¦8Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ »ý¸®Åë Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â) ¹× ¿¹Ãø(2024-2031³â)
Á¦9Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ »ý¸®Åë Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â) ¹× ¿¹Ãø(2024-2031³â)
Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ »ý¸®Åë Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â) ¹× ¿¹Ãø(2024-2031³â)
Á¦11Àå °æÀï »óȲ
½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â
½ÃÀå ±¸Á¶
½ÃÀ庰 °æÀï °ÝÈ ¸Ê
°æÀï ´ë½Ãº¸µå
°Ñº¸±â Á¦Ç° ¿ë·®
±â¾÷ °³¿ä(»ó¼¼ - °³¿ä, À繫, Àü·«, ÃÖ±ÙÀÇ µ¿Çâ)
Novartis Pharmaceuticals Corporation
Merck, Inc.
Bayer Schering Pharma AG
Vanita Therapeutics
Alvogen
Pfizer, Inc.
Nua
Cora
Roche Laboratories
Taj Pharmaceuticals, Ltd.
Sanofi
Terramedic, Inc.
Á¦12Àå ºÎ·Ï
Á¶»ç ¹æ¹ý
Á¶»ç °¡Á¤
µÎ¹®ÀÚ¾î¿Í ¾à¾î
ksm
¿µ¹® ¸ñÂ÷
Persistence Market Research has recently released a comprehensive report on the global Dysmenorrhea Treatment Market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.
Key Insights:
Dysmenorrhea Treatment Market Size (2024E): USD 6.1 Billion
Projected Market Value (2031F): USD 10.9 Billion
Global Market Growth Rate (CAGR 2024 to 2031): 8.6%
Dysmenorrhea Treatment Market - Report Scope:
Dysmenorrhea, characterized by painful menstrual cramps, impacts a significant portion of the female population globally. The Dysmenorrhea Treatment Market caters to a wide range of therapeutic options, including pharmaceuticals, over-the-counter pain relievers, hormonal treatments, and alternative medicine. Market growth is driven by the increasing prevalence of dysmenorrhea, rising awareness of treatment options, and advancements in medical research aimed at improving symptom management and patient quality of life.
Market Growth Drivers:
The global Dysmenorrhea Treatment Market is propelled by several key factors, including growing awareness about the availability of effective treatment options and the increasing prevalence of dysmenorrhea among women of reproductive age. Advances in drug formulations and the development of novel therapies, such as non-hormonal medications and targeted therapies, contribute to the market's expansion. Additionally, rising healthcare expenditures and the availability of diverse treatment options in both developed and emerging markets further drive market growth.
Market Restraints:
Despite promising growth prospects, the Dysmenorrhea Treatment Market faces challenges related to the high cost of advanced treatment options and limited access to healthcare in certain regions. Variability in treatment efficacy and patient adherence issues also pose challenges. Furthermore, regulatory hurdles and the need for ongoing clinical trials to validate new therapies can impact market dynamics and slow the introduction of innovative treatment solutions.
Market Opportunities:
The Dysmenorrhea Treatment Market presents significant growth opportunities driven by technological innovations, increasing investment in research and development, and the growing focus on personalized medicine. The integration of digital health technologies, such as mobile health apps for symptom tracking and telemedicine platforms, enhances patient access to care and improves treatment adherence. Furthermore, expanding awareness campaigns and educational programs about dysmenorrhea and its treatment options can foster market growth and encourage early diagnosis and effective management.
Key Questions Answered in the Report:
What are the primary factors driving the growth of the Dysmenorrhea Treatment Market globally?
Which treatment options and approaches are most effective in managing dysmenorrhea?
How are technological advancements and research innovations influencing the competitive landscape of the Dysmenorrhea Treatment Market?
Who are the key players contributing to the Dysmenorrhea Treatment Market, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global Dysmenorrhea Treatment Market?
Competitive Intelligence and Business Strategy:
Leading players in the global Dysmenorrhea Treatment Market, including Pfizer Inc., Bayer AG, and Johnson & Johnson, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced treatment options, including novel pain management therapies and hormone-based treatments. Collaborations with healthcare providers, academic institutions, and regulatory agencies facilitate market access and promote technology adoption. Additionally, emphasis on clinical research, patient education, and targeted marketing strategies support market growth and enhance patient outcomes in the evolving Dysmenorrhea Treatment landscape.
Key Companies Profiled:
Novartis Pharmaceuticals Corporation
Merck, Inc.
Bayer Schering Pharma AG
Vanita Therapeutics
Alvogen
Pfizer, Inc.
Nua
Cora
Roche Laboratories
Taj Pharmaceuticals, Ltd.
Sanofi
Terramedic, Inc.
Dysmenorrhea Treatment Market Research Segmentation
By Diseases:
Primary Dysmenorrhea
Secondary Dysmenorrhea
Endometriosis
Adenomyosis
Uterine Myomas
Endometrial Polyps
Cervical Stenosis
Obstructive Malformations of Genital Tract
By Therapeutic Class:
Non-Hormonal Medical Treatment
Non-steroidal anti-inflammatory Drugs (NSAIDS)
Non-Selective NSAIDs
Cox-2 Inhibitors
Transdermal Glyceryl Trinitrate
Over-The-Counter (Otc) Medications
Hormonal Medicine Treatment
Combined Oral Contraceptive
Progestin Regimens
Levonorgestrel Intrauterine System (LN-IUS)
Surgical Options
Laparoscopy
Hysterectomy
Presacral Neurectomy
Laparoscopic Uterosacral Nerve Ablation (LUNA)
Intrauterine Device (IUD)
By Region:
North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa
Table of Contents
1. Executive Summary
1.1. Global Dysmenorrhea Treatment Market Snapshot, 2024 - 2031
1.2. Market Opportunity Assessment, 2024 - 2031, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Diseases Lifecycle Analysis
2.4. Dysmenorrhea Treatment Market: Value Chain
2.4.1. List of Raw Material Supplier
2.4.2. List of Manufacturers
2.4.3. List of Distributors
2.4.4. List of Applications
2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
2.7.1. Global Sectorial Outlook
2.7.2. Global GDP Growth Outlook
2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Technology Landscape
3. Global Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)
3.1. Key Highlights
3.1.1. Market Volume (Units) Projections
3.1.2. Market Size and Y-o-Y Growth
3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Bn) Analysis and Forecast
3.2.1. Historical Market Size Analysis, 2019-2023
3.2.2. Current Market Size Forecast, 2024 - 2031
3.3. Global Dysmenorrhea Treatment Market Outlook: Diseases
3.3.1. Introduction / Key Findings
3.3.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Disease, 2019-2023
3.3.3. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
3.3.3.1. Primary Dysmenorrhea
3.3.3.2. Secondary Dysmenorrhea
3.3.3.3. Endometriosis
3.3.3.4. Adenomyosis
3.3.3.5. Uterine Myomas
3.3.3.6. Endometrial Polyps
3.3.3.7. Cervical Stenosis
3.3.3.8. Obstructive Malformations of Genital Tract
3.4. Market Attractiveness Analysis: Diseases
3.5. Global Dysmenorrhea Treatment Market Outlook: Therapeutic Class
3.5.1. Introduction / Key Findings
3.5.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Therapeutic Class, 2019-2023
3.5.3. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
3.5.3.1. Non-Hormonal Medical Treatment
3.5.3.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
3.5.3.3. Non-Selective Nsaids
3.5.3.4. Cox-2 Inhibitors
3.5.3.5. Transdermal Glyceryl Trinitrate
3.5.3.6. Over-The-Counter (Otc) Medications
3.5.3.7. Hormonal Medicine Treatment
3.5.3.8. Combined Oral Contraceptive
3.5.3.9. Progestin Regimens
3.5.3.10. Levonorgestrel Intrauterine System (LN-IUS)
3.5.3.11. Surgical Options
3.5.3.12. Laparoscopy
3.5.3.13. Hysterectomy
3.5.3.14. Presacral Neurectomy
3.5.3.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
3.5.3.16. Intrauterine Device (IUD)
3.6. Market Attractiveness Analysis: Therapeutic Class
4. Global Dysmenorrhea Treatment Market Outlook: Region
4.1. Key Highlights
4.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Region, 2019-2023
4.3. Current Market Size (US$ Bn) and Volume (Units) Forecast By Region, 2024 - 2031
4.3.1. North America
4.3.2. Europe
4.3.3. East Asia
4.3.4. South Asia and Oceania
4.3.5. Latin America
4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region
5. North America Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)
5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
5.3.1. By Country
5.3.2. By Disease
5.3.3. By Therapeutic Class
5.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024 - 2031
5.4.1. U.S.
5.4.2. Canada
5.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
5.5.1. Primary Dysmenorrhea
5.5.2. Secondary Dysmenorrhea
5.5.3. Endometriosis
5.5.4. Adenomyosis
5.5.5. Uterine Myomas
5.5.6. Endometrial Polyps
5.5.7. Cervical Stenosis
5.5.8. Obstructive Malformations of Genital Tract
5.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
5.6.1. Non-Hormonal Medical Treatment
5.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
5.6.3. Non-Selective Nsaids
5.6.4. Cox-2 Inhibitors
5.6.5. Transdermal Glyceryl Trinitrate
5.6.6. Over-The-Counter (Otc) Medications
5.6.7. Hormonal Medicine Treatment
5.6.8. Combined Oral Contraceptive
5.6.9. Progestin Regimens
5.6.10. Levonorgestrel Intrauterine System (LN-IUS)
5.6.11. Surgical Options
5.6.12. Laparoscopy
5.6.13. Hysterectomy
5.6.14. Presacral Neurectomy
5.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
5.6.16. Intrauterine Device (IUD)
5.7. Market Attractiveness Analysis
6. Europe Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
6.3.1. By Country
6.3.2. By Disease
6.3.3. By Therapeutic Class
6.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024 - 2031
6.4.1. Germany
6.4.2. France
6.4.3. U.K.
6.4.4. Italy
6.4.5. Spain
6.4.6. Russia
6.4.7. Turkiye
6.4.8. Rest of Europe
6.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
6.5.1. Primary Dysmenorrhea
6.5.2. Secondary Dysmenorrhea
6.5.3. Endometriosis
6.5.4. Adenomyosis
6.5.5. Uterine Myomas
6.5.6. Endometrial Polyps
6.5.7. Cervical Stenosis
6.5.8. Obstructive Malformations of Genital Tract
6.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
6.6.1. Non-Hormonal Medical Treatment
6.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
6.6.3. Non-Selective Nsaids
6.6.4. Cox-2 Inhibitors
6.6.5. Transdermal Glyceryl Trinitrate
6.6.6. Over-The-Counter (Otc) Medications
6.6.7. Hormonal Medicine Treatment
6.6.8. Combined Oral Contraceptive
6.6.9. Progestin Regimens
6.6.10. Levonorgestrel Intrauterine System (LN-IUS)
6.6.11. Surgical Options
6.6.12. Laparoscopy
6.6.13. Hysterectomy
6.6.14. Presacral Neurectomy
6.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
6.6.16. Intrauterine Device (IUD)
6.7. Market Attractiveness Analysis
7. East Asia Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
7.3.1. By Country
7.3.2. By Disease
7.3.3. By Therapeutic Class
7.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024 - 2031
7.4.1. China
7.4.2. Japan
7.4.3. South Korea
7.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
7.5.1. Primary Dysmenorrhea
7.5.2. Secondary Dysmenorrhea
7.5.3. Endometriosis
7.5.4. Adenomyosis
7.5.5. Uterine Myomas
7.5.6. Endometrial Polyps
7.5.7. Cervical Stenosis
7.5.8. Obstructive Malformations of Genital Tract
7.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
7.6.1. Non-Hormonal Medical Treatment
7.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
7.6.3. Non-Selective Nsaids
7.6.4. Cox-2 Inhibitors
7.6.5. Transdermal Glyceryl Trinitrate
7.6.6. Over-The-Counter (Otc) Medications
7.6.7. Hormonal Medicine Treatment
7.6.8. Combined Oral Contraceptive
7.6.9. Progestin Regimens
7.6.10. Levonorgestrel Intrauterine System (LN-IUS)
7.6.11. Surgical Options
7.6.12. Laparoscopy
7.6.13. Hysterectomy
7.6.14. Presacral Neurectomy
7.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
7.6.16. Intrauterine Device (IUD)
7.7. Market Attractiveness Analysis
8. South Asia & Oceania Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
8.3.1. By Country
8.3.2. By Disease
8.3.3. By Therapeutic Class
8.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024 - 2031
8.4.1. India
8.4.2. Southeast Asia
8.4.3. ANZ
8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
8.5.1. Primary Dysmenorrhea
8.5.2. Secondary Dysmenorrhea
8.5.3. Endometriosis
8.5.4. Adenomyosis
8.5.5. Uterine Myomas
8.5.6. Endometrial Polyps
8.5.7. Cervical Stenosis
8.5.8. Obstructive Malformations of Genital Tract
8.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
8.6.1. Non-Hormonal Medical Treatment
8.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
8.6.3. Non-Selective Nsaids
8.6.4. Cox-2 Inhibitors
8.6.5. Transdermal Glyceryl Trinitrate
8.6.6. Over-The-Counter (Otc) Medications
8.6.7. Hormonal Medicine Treatment
8.6.8. Combined Oral Contraceptive
8.6.9. Progestin Regimens
8.6.10. Levonorgestrel Intrauterine System (LN-IUS)
8.6.11. Surgical Options
8.6.12. Laparoscopy
8.6.13. Hysterectomy
8.6.14. Presacral Neurectomy
8.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
8.6.16. Intrauterine Device (IUD)
8.7. Market Attractiveness Analysis
9. Latin America Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
9.3.1. By Country
9.3.2. By Disease
9.3.3. By Therapeutic Class
9.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024 - 2031
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
9.5.1. Primary Dysmenorrhea
9.5.2. Secondary Dysmenorrhea
9.5.3. Endometriosis
9.5.4. Adenomyosis
9.5.5. Uterine Myomas
9.5.6. Endometrial Polyps
9.5.7. Cervical Stenosis
9.5.8. Obstructive Malformations of Genital Tract
9.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
9.6.1. Non-Hormonal Medical Treatment
9.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
9.6.3. Non-Selective Nsaids
9.6.4. Cox-2 Inhibitors
9.6.5. Transdermal Glyceryl Trinitrate
9.6.6. Over-The-Counter (Otc) Medications
9.6.7. Hormonal Medicine Treatment
9.6.8. Combined Oral Contraceptive
9.6.9. Progestin Regimens
9.6.10. Levonorgestrel Intrauterine System (LN-IUS)
9.6.11. Surgical Options
9.6.12. Laparoscopy
9.6.13. Hysterectomy
9.6.14. Presacral Neurectomy
9.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
9.6.16. Intrauterine Device (IUD)
9.7. Market Attractiveness Analysis
10. Middle East & Africa Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
10.3.1. By Country
10.3.2. By Disease
10.3.3. By Therapeutic Class
10.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024 - 2031
10.4.1. GCC
10.4.2. Egypt
10.4.3. South Africa
10.4.4. Northern Africa
10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
10.5.1. Primary Dysmenorrhea
10.5.2. Secondary Dysmenorrhea
10.5.3. Endometriosis
10.5.4. Adenomyosis
10.5.5. Uterine Myomas
10.5.6. Endometrial Polyps
10.5.7. Cervical Stenosis
10.5.8. Obstructive Malformations of Genital Tract
10.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
10.6.1. Non-Hormonal Medical Treatment
10.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
10.6.3. Non-Selective Nsaids
10.6.4. Cox-2 Inhibitors
10.6.5. Transdermal Glyceryl Trinitrate
10.6.6. Over-The-Counter (Otc) Medications
10.6.7. Hormonal Medicine Treatment
10.6.8. Combined Oral Contraceptive
10.6.9. Progestin Regimens
10.6.10. Levonorgestrel Intrauterine System (LN-IUS)
10.6.11. Surgical Options
10.6.12. Laparoscopy
10.6.13. Hysterectomy
10.6.14. Presacral Neurectomy
10.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
10.6.16. Intrauterine Device (IUD)
10.7. Market Attractiveness Analysis
11. Competition Landscape
11.1. Market Share Analysis, 2024
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition Dashboard
11.2.3. Apparent Product Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
11.3.1. Novartis Pharmaceuticals Corporation
11.3.1.1. Overview
11.3.1.2. Segments and Product
11.3.1.3. Key Financials
11.3.1.4. Market Developments
11.3.1.5. Market Strategy
11.3.2. Merck, Inc.
11.3.2.1. Overview
11.3.2.2. Segments and Product
11.3.2.3. Key Financials
11.3.2.4. Market Developments
11.3.2.5. Market Strategy
11.3.3. Bayer Schering Pharma AG
11.3.3.1. Overview
11.3.3.2. Segments and Product
11.3.3.3. Key Financials
11.3.3.4. Market Developments
11.3.3.5. Market Strategy
11.3.4. Vanita Therapeutics
11.3.4.1. Overview
11.3.4.2. Segments and Product
11.3.4.3. Key Financials
11.3.4.4. Market Developments
11.3.4.5. Market Strategy
11.3.5. Alvogen
11.3.5.1. Overview
11.3.5.2. Segments and Product
11.3.5.3. Key Financials
11.3.5.4. Market Developments
11.3.5.5. Market Strategy
11.3.6. Pfizer, Inc.
11.3.6.1. Overview
11.3.6.2. Segments and Product
11.3.6.3. Key Financials
11.3.6.4. Market Developments
11.3.6.5. Market Strategy
11.3.7. Nua
11.3.7.1. Overview
11.3.7.2. Segments and Product
11.3.7.3. Key Financials
11.3.7.4. Market Developments
11.3.7.5. Market Strategy
11.3.8. Cora
11.3.8.1. Overview
11.3.8.2. Segments and Product
11.3.8.3. Key Financials
11.3.8.4. Market Developments
11.3.8.5. Market Strategy
11.3.9. Roche Laboratories
11.3.9.1. Overview
11.3.9.2. Segments and Product
11.3.9.3. Key Financials
11.3.9.4. Market Developments
11.3.9.5. Market Strategy
11.3.10. Taj Pharmaceuticals, Ltd.
11.3.10.1. Overview
11.3.10.2. Segments and Product
11.3.10.3. Key Financials
11.3.10.4. Market Developments
11.3.10.5. Market Strategy
11.3.11. Sanofi
11.3.11.1. Overview
11.3.11.2. Segments and Product
11.3.11.3. Key Financials
11.3.11.4. Market Developments
11.3.11.5. Market Strategy
11.3.12. Terramedic, Inc.
11.3.12.1. Overview
11.3.12.2. Segments and Product
11.3.12.3. Key Financials
11.3.12.4. Market Developments
11.3.12.5. Market Strategy
12. Appendix
12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations
°ü·ÃÀÚ·á